blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3645024

EP3645024 - SYNBIOTIC COMPOSITION FOR PREVENTING FATTY LIVER DISEASE [Right-click to bookmark this link]
Former [2020/19]SYNBIOTIC COMPOSITION FOR PREVENTING METABOLIC DISORDERS
[2022/17]
StatusNo opposition filed within time limit
Status updated on  21.07.2023
Database last updated on 24.04.2024
FormerThe patent has been granted
Status updated on  12.08.2022
FormerGrant of patent is intended
Status updated on  10.04.2022
FormerExamination is in progress
Status updated on  29.01.2021
FormerRequest for examination was made
Status updated on  03.04.2020
FormerThe international publication has been made
Status updated on  04.01.2019
Formerunknown
Status updated on  04.07.2018
Most recent event   Tooltip26.01.2024Lapse of the patent in a contracting state
New state(s): MC		published on 28.02.2024  [2024/09]
Applicant(s)For all designated states
N.V. Nutricia
Eerste Stationsstraat 186
2712 HM Zoetermeer / NL
[2020/19]
Inventor(s)01 / ENGELS, Eefje
Uppsalalaan 12
3584 CT Utrecht / NL
02 / VAN LIMPT, Cornelus Johannes Petrus
Uppsalalaan 12
3584 CT Utrecht / NL
03 / OOSTING, Annemarie
Uppsalalaan 12
3584 CT Utrecht / NL
04 / OOZEER, Akhtar Raish
Uppsalalaan 12
3584 CT Utrecht / NL
05 / KNOL, Jan
Uppsalalaan 12
3584 CT Utrecht / NL
06 / MISCHKE, Mona
Uppsalalaan 12
3584 CT Utrecht / NL
 [2020/19]
Representative(s)Nederlandsch Octrooibureau
P.O. Box 29720
2502 LS The Hague / NL
[2020/19]
Application number, filing date18733320.829.06.2018
[2020/19]
WO2018EP67706
Priority number, dateEP2017017912430.06.2017         Original published format: EP 17179124
[2020/19]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2019002609
Date:03.01.2019
Language:EN
[2019/01]
Type: A1 Application with search report 
No.:EP3645024
Date:06.05.2020
Language:EN
The application published by WIPO in one of the EPO official languages on 03.01.2019 takes the place of the publication of the European patent application.
[2020/19]
Type: B1 Patent specification 
No.:EP3645024
Date:14.09.2022
Language:EN
[2022/37]
Search report(s)International search report - published on:EP03.01.2019
ClassificationIPC:A61K35/745, A61K9/00, A61K31/715, A23L33/00, A23L33/135, A23L33/21, A61P3/06
[2020/19]
CPC:
A61K35/745 (EP,US); A23L33/135 (EP,US); A23L33/21 (EP,US);
A23L33/40 (EP,US); A61K31/702 (US); A61K31/715 (EP,US);
A61K9/0095 (EP,US); A61P3/06 (US); A61P3/10 (US);
A23V2002/00 (US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2020/19]
Extension statesBANot yet paid
MENot yet paid
Validation statesKHNot yet paid
MANot yet paid
MDNot yet paid
TNNot yet paid
TitleGerman:SYMBIOTISCHE ZUSAMMENSETZUNG ZUR PRÄVENTION VON FETTLEBERERKRANKUNG[2022/17]
English:SYNBIOTIC COMPOSITION FOR PREVENTING FATTY LIVER DISEASE[2022/17]
French:COMPOSITION SYMBIOTIQUE DE PRÉVENTION DE LA STÉATOSE HÉPATIQUE[2022/17]
Former [2020/19]SYMBIOTISCHE ZUSAMMENSETZUNG ZUR PRÄVENTION VON METABOLISCHEN ERKRANKUNGEN
Former [2020/19]SYNBIOTIC COMPOSITION FOR PREVENTING METABOLIC DISORDERS
Former [2020/19]COMPOSITION SYMBIOTIQUE POUR LA PRÉVENTION DE TROUBLES MÉTABOLIQUES
Entry into regional phase17.01.2020National basic fee paid 
17.01.2020Designation fee(s) paid 
17.01.2020Examination fee paid 
Examination procedure30.04.2019Request for preliminary examination filed
International Preliminary Examining Authority: EP
17.01.2020Examination requested  [2020/19]
17.01.2020Date on which the examining division has become responsible
24.08.2020Amendment by applicant (claims and/or description)
02.02.2021Despatch of a communication from the examining division (Time limit: M06)
29.07.2021Reply to a communication from the examining division
11.04.2022Communication of intention to grant the patent
08.08.2022Fee for grant paid
08.08.2022Fee for publishing/printing paid
08.08.2022Receipt of the translation of the claim(s)
Opposition(s)15.06.2023No opposition filed within time limit [2023/34]
Fees paidRenewal fee
12.06.2020Renewal fee patent year 03
30.04.2021Renewal fee patent year 04
23.06.2022Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL14.09.2022
AT14.09.2022
CZ14.09.2022
DK14.09.2022
EE14.09.2022
ES14.09.2022
FI14.09.2022
HR14.09.2022
LT14.09.2022
LV14.09.2022
MC14.09.2022
PL14.09.2022
RO14.09.2022
RS14.09.2022
SE14.09.2022
SI14.09.2022
SK14.09.2022
SM14.09.2022
NO14.12.2022
GR15.12.2022
IS14.01.2023
PT16.01.2023
[2024/09]
Former [2023/37]AL14.09.2022
AT14.09.2022
CZ14.09.2022
DK14.09.2022
EE14.09.2022
ES14.09.2022
FI14.09.2022
HR14.09.2022
LT14.09.2022
LV14.09.2022
PL14.09.2022
RO14.09.2022
RS14.09.2022
SE14.09.2022
SI14.09.2022
SK14.09.2022
SM14.09.2022
NO14.12.2022
GR15.12.2022
IS14.01.2023
PT16.01.2023
Former [2023/34]AL14.09.2022
AT14.09.2022
CZ14.09.2022
DK14.09.2022
EE14.09.2022
ES14.09.2022
FI14.09.2022
HR14.09.2022
LT14.09.2022
LV14.09.2022
PL14.09.2022
RO14.09.2022
RS14.09.2022
SE14.09.2022
SK14.09.2022
SM14.09.2022
NO14.12.2022
GR15.12.2022
IS14.01.2023
PT16.01.2023
Former [2023/29]AL14.09.2022
AT14.09.2022
CZ14.09.2022
EE14.09.2022
ES14.09.2022
FI14.09.2022
HR14.09.2022
LT14.09.2022
LV14.09.2022
PL14.09.2022
RO14.09.2022
RS14.09.2022
SE14.09.2022
SK14.09.2022
SM14.09.2022
NO14.12.2022
GR15.12.2022
IS14.01.2023
PT16.01.2023
Former [2023/26]AT14.09.2022
CZ14.09.2022
EE14.09.2022
ES14.09.2022
FI14.09.2022
HR14.09.2022
LT14.09.2022
LV14.09.2022
PL14.09.2022
RO14.09.2022
RS14.09.2022
SE14.09.2022
SK14.09.2022
SM14.09.2022
NO14.12.2022
GR15.12.2022
IS14.01.2023
PT16.01.2023
Former [2023/23]AT14.09.2022
CZ14.09.2022
EE14.09.2022
ES14.09.2022
FI14.09.2022
HR14.09.2022
LT14.09.2022
LV14.09.2022
RO14.09.2022
RS14.09.2022
SE14.09.2022
SK14.09.2022
SM14.09.2022
NO14.12.2022
GR15.12.2022
PT16.01.2023
Former [2023/22]AT14.09.2022
CZ14.09.2022
ES14.09.2022
FI14.09.2022
HR14.09.2022
LT14.09.2022
LV14.09.2022
RO14.09.2022
RS14.09.2022
SE14.09.2022
SM14.09.2022
NO14.12.2022
GR15.12.2022
PT16.01.2023
Former [2023/20]FI14.09.2022
HR14.09.2022
LT14.09.2022
LV14.09.2022
RS14.09.2022
SE14.09.2022
SM14.09.2022
NO14.12.2022
GR15.12.2022
Former [2023/10]FI14.09.2022
HR14.09.2022
LT14.09.2022
LV14.09.2022
RS14.09.2022
SE14.09.2022
NO14.12.2022
GR15.12.2022
Former [2023/09]FI14.09.2022
LT14.09.2022
LV14.09.2022
RS14.09.2022
SE14.09.2022
NO14.12.2022
Former [2023/08]FI14.09.2022
LT14.09.2022
RS14.09.2022
SE14.09.2022
NO14.12.2022
Cited inInternational search[Y]WO9949877  (GANEDEN BIOTECH INC [US], et al) [Y] 1-13 * claims 1,7,13,30,37,39,60,62 *;
 [YD]WO2006091103  (NUTRICIA NV [NL], et al) [YD] 1-13 * page 14; claims 1,13,16 *;
 [Y]WO2008116700  (NESTEC SA [CH], et al) [Y] 1-13 * claims 1-11 *;
 [Y]EP2143341  (NESTEC SA [CH]) [Y] 1-13 * paragraph [0024]; claims 1,15,17 *;
 [Y]EP2359838  (ARAGAN [FR]) [Y] 1-13 * paragraphs [0050] , [0072]; claim 14 *;
 [Y]EP2452571  (NESTEC SA [CH]) [Y] 1-13 * paragraph [0037]; claims 4,7,17-19 *;
 [Y]WO2012153179  (PROBIOTICAL SPA [IT], et al) [Y] 1-13 * claims 1,2,5,11,12 *;
 [Y]WO2013054002  (GUT GUIDE OY [FI]) [Y] 1-13 * paragraph [0018]; example 3; claims 1-3 *;
 [XYI]WO2015172191  (MEDLAB IP PTY LTD [AU]) [X] 1,2,5,8,12,13 * paragraphs [0127] , [0129] , [0136]; claims 3-6 * [Y] 7 [I] 3,4,6,9-11;
 [Y]WO2016020495  (NESTEC SA [CH]) [Y] 1-13 * page 18, paragraph 1 * * claims 1,8,10 *;
 [Y]WO2016026684  (NESTEC SA [CH]) [Y] 1-13 * claims 1-11 *;
 [Y]WO2017043963  (NUTRICIA NV [NL]) [Y] 1-13 * example 1; claim 1 *;
 [XP]WO2017129649  (NESTEC SA [CH]) [XP] 1-13 * claims 10,18 *;
 [XP]WO2017145415  (MORINAGA MILK INDUSTRY CO LTD [JP]) [XP] 1-13 * paragraphs [0029] - [0034] - [0039] , [0085]; claim 7 *;
 [Y]  - KUITUNEN M ET AL, "Probiotics prevent IgE-associated allergy until age 5 years in cesarean-delivered children but not in the total cohort", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 123, no. 2, doi:10.1016/J.JACI.2008.11.019, ISSN 0091-6749, (20090201), pages 335 - 341, (20090108), XP025907147 [Y] 1-13 * page 335 *

DOI:   http://dx.doi.org/10.1016/j.jaci.2008.11.019
 [Y]  - ZATOLLAH ASEMI ET AL, "Effect of Multispecies Probiotic Supplements on Metabolic Profiles, hs-CRP, and Oxidative Stress in Patients with Type 2 Diabetes", ANNALS OF NUTRITION AND METABOLISM: EUROPEAN JOURNAL OF NUTRITION, METABOLIC DISEASES AND DIETETICS, Switzerland, (20130101), vol. 63, no. 1-2, doi:10.1159/000349922, ISSN 0250-6807, pages 1 - 9, XP055433345 [Y] 1-13 * page 2 *

DOI:   http://dx.doi.org/10.1159/000349922
 [Y]  - FATEMEH MOFIDI ET AL, "Abstract", BRITISH JOURNAL OF NUTRITION, UK, (20170314), vol. 117, no. 05, doi:10.1017/S0007114517000204, ISSN 0007-1145, pages 662 - 668, XP055432710 [Y] 1-13 * page 663 *

DOI:   http://dx.doi.org/10.1017/S0007114517000204
 [Y]  - P. D. CANI ET AL, "Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia", DIABETOLOGIA, (20070906), vol. 50, no. 11, doi:10.1007/s00125-007-0791-0, ISSN 0012-186X, pages 2374 - 2383, XP055179453 [Y] 1-13 * page 2375 *

DOI:   http://dx.doi.org/10.1007/s00125-007-0791-0
 [Y]  - SHIZUKI KONDO ET AL, "Antiobesity effects of bifidobacterium breve strain B-3 supplementation in a mouse model with high-fat diet-induced obesity", BIOSCIENCE BIOTECHNOLOGY BIOCHEMIS, JAPAN SOCIETY FOR BIOSCIENCE, BIOTECHNOLOGY, AND AGROCHEMISTRY, TOKYO, JAPAN, vol. 74, no. 8, doi:10.1271/BBB.100267, ISSN 0916-8451, (20100823), pages 1656 - 1661, (20100807), XP008161355 [Y] 1-13 * page 1657 *

DOI:   http://dx.doi.org/10.1271/bbb.100267
 [Y]  - TANNAZ ESLAMPARAST ET AL, "Effects of synbiotic supplementation on insulin resistance in subjects with the metabolic syndrome: a randomised, double-blind, placebo-controlled pilot study", BRITISH JOURNAL OF NUTRITION, UK, (20140801), vol. 112, no. 03, doi:10.1017/S0007114514000919, ISSN 0007-1145, pages 438 - 445, XP055432712 [Y] 1-13 * page 439 *

DOI:   http://dx.doi.org/10.1017/S0007114514000919
 [Y]  - MICHELE MALAGUARNERA ET AL, "with Fructo-Oligosaccharides in Patients with Non Alcoholic Steatohepatitis", DIGESTIVE DISEASES AND SCIENCES, KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NE, (20110908), vol. 57, no. 2, doi:10.1007/S10620-011-1887-4, ISSN 1573-2568, pages 545 - 553, XP035005634 [Y] 1-13 * page 546 *

DOI:   http://dx.doi.org/10.1007/s10620-011-1887-4
 [Y]  - CAMILA MOROTI ET AL, "Effect of the consumption of a new symbiotic shake on glycemia and cholesterol levels in elderly people with type 2 diabetes mellitus", LIPIDS IN HEALTH AND DISEASE, BIOMED CENTRAL, LONDON, GB, (20120222), vol. 11, no. 1, doi:10.1186/1476-511X-11-29, ISSN 1476-511X, page 29, XP021118593 [Y] 1-13 * page 2 *

DOI:   http://dx.doi.org/10.1186/1476-511X-11-29
 [Y]  - HAKIKI MELANIE ET AL, "Fermented inulin hydrolysate by Bifidobacterium breve as cholesterol binder in functional food application", AIP CONFERENCE PROCEEDINGS, NEW YORK, US, (20170101), vol. 1803, doi:10.1063/1.4973161, ISSN 0094-243X, pages 020034 - 1, XP055458805 [Y] 1-13 * pages 020034-2 *

DOI:   http://dx.doi.org/10.1063/1.4973161
 [Y]  - OOI LAY-GAIK ET AL, "Cholesterol-lowering effects of probiotics and prebiotics: a review of in vivo and in vitro findings", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, MOLECULAR DIVERSITY PRESERVATION INTERNATIONAL, BASEL, CH, (20100617), vol. 11, no. 6, doi:10.3390/IJMS11062499, ISSN 1422-0067, pages 2499 - 2522, XP002665634 [Y] 1-13 * page 2513 *

DOI:   http://dx.doi.org/10.3390/IJMS11062499
 [Y]  - J.P. GRILL ET AL, "Effects of Lactobacillus amylovorus and Bifidobacterium breve on cholesterol", LETTERS IN APPLIED MICROBIOLOGY, GB, (20000801), vol. 31, no. 2, doi:10.1046/j.1365-2672.2000.00792.x, ISSN 0266-8254, pages 154 - 156, XP055458967 [Y] 1-13 * page 155 *

DOI:   http://dx.doi.org/10.1046/j.1365-2672.2000.00792.x
 [XP]  - MONA MISCHKE ET AL, "Specific synbiotics in early life protect against diet-induced obesity in adult mice", DIABETES, OBESITY AND METABOLISM, (20180220), vol. 20, no. 6, doi:10.1111/dom.13240, ISSN 1462-8902, pages 1408 - 1418, XP055504709 [XP] 1-13 * page 1408 *

DOI:   http://dx.doi.org/10.1111/dom.13240
by applicantWO2004093899
 WO2006091103
 US7410653
 WO2011096808
 WO2013036102
 US9386793
    - STACKEBRANDT; GOEBEL, Int. J. Syst. Bacteriol., (19940000), vol. 44, pages 846 - 849
    - L. PROSKY et al., J. Assoc. Off. Anal. Chem., (19880000), vol. 71, pages 1017 - 1023
    - SWINBURN et al., Prev Med, (19990000), vol. 29, pages 563 - 570
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.